Clare Bryant

Professor of Innate Immunity
University of Cambridge

The Bryant group collaborates closely with academics in the USA, Europe and Australia to perform cutting edge innate immunity research. A vital part of our work is to forge, and maintain, strong collaborations with the pharmaceutical industry to translate our research into medicines. We have close links to Genentech (Clare was a visiting professor there in 2016 and 2017). Clare was seconded to GSK in Stevenage as part of their Immunology Catalyst program for 3 years to forge stronger links with academia. Clare has a drug discovery program with Apollo Therapeutics looking for novel therapeutics against TLR4 as potential treatments for Alzheimer’s disease and asthma. Clare has a start up company, has collaborative grants with different pharmaceutical companies and she currently is on the scientific advisory board and/or consults for a number of biotech companies in the UK and the USA.